地角天边
江郎才尽,不足为训
指南：http://bbs.wenxuecity.com/health/538930.html
淋巴癌：http://www.lymphomafacts.org/site/c.gtJSJbMUIuE/b.1354083/k.7095/2810724052302843034022522264123069335672_Facts.htm
其它癌症：http://www.cnaizheng.com/zl/azzl/guai/Index.htm
肺癌： http://www.guokr.com/article/437125/
生存率： http://theconversation.com/hard-evidence-are-we-beating-cancer-20870
问医生： http://bbs.wenxuecity.com/health/529178.html
谢文纬： http://yyk.39.net/doctor/307364_detail.html
国内肿瘤医生：http://hailiu.haodf.com/lanmu
去癌散：http://blog.sina.com.cn/s/blog_4c40adce01000auy.html
1.淋巴瘤都是癌性的，半存活率5-10年。
淋巴癌最大的病徵就是淋巴結腫大，其中以頸部淋巴結腫大最常見，其次是腋下、鼠蹊部位，他提醒一旦出現慢性、進行性、無痛性的淋巴結腫大，應儘早接受切片檢查。
2.
Follicular lymphoma尽管进展极其缓慢，但却被称为不可治愈的。而aggressive and very aggressive的淋巴瘤，尽管会进展快，但很大部分病人是可以治愈的，所以要积极治疗，这个看起来很矛盾。Hodgkin治愈率更高（不要和FL搞混了）。还有个有意思的现象，尽管化疗后follicullar lymphoma会很快消失，但以后还会出现，其进展速度和没有治疗的差不多，因而生存时间和生存率也没有什么差别，于是对这个病，人们一般不主张在一开始就化疗，而是在需要治疗时（有了症状--全身的或局部的，肿块大或有压迫时，或有贫血等等）再治疗。一旦需要治疗，化疗效果不错。也就是说，你有了这个病，活得好好的时候，就不要管他。它造成问题了，咱再治疗。因为早治疗和晚治疗的结果是一样的，为啥要早治早有副作用呢？
对早期在外周淋巴区的FL，如腋窝和腹股沟的，却主张用放疗，为啥？以前的临床研究发现，早期follicular lymphoma放疗后很多人长时间无病生存，10年甚至20年近35-40%无复发，而且过了十几年后复发率更少，所以有人把这个情况说成“治愈”，带引号的。但那有人问了，为啥三大作风的医生不主张治疗？因为腹部淋巴区较大，照射范围大，有很多器官，尽管剂量低，但长期副作用不能不考虑，譬如放射致癌风险，所以对腹部的，不主张放疗。这一点，可能有的医生会有不同看法，但多数是不主张治疗的。这是个收益和风险的比例问题。
如何做watchful waiting?一般是定期CT。为啥不用MRI？MRI费用贵，而且胸部一般不用MRI，其他区域CT和MRI差不多，当然就选CT了。而且CT扫起来快，“哧溜”一下就完了。
还有，病理做了那么markers,主要是鉴别诊断用。譬如，CD5 和CyclinD1是另一种淋巴瘤的标志，叫Mantle cell lymphoma,显微镜下和FL相似，而这两个markers可以鉴别诊断。Cyclin是细胞周期因子的意思. 因为Cyclin一般是推动细胞周期的，也就是使细胞增殖的，不是个好东西。Mantle cell lymphoma的生存以前平均只有三年，现在好些，估计4-6年，比FL差好多。所以，CyclinD1阴性，该是个好事。
另外，在淋巴结里见到大量的T淋巴细胞，不一定有什么预后意义。在其他地方的肿瘤，有大量淋巴浸润，是个好 现象。但淋巴结是淋巴细胞的家，看到了正常。就像一个贪官和情妇在商场里逛商店时被警察抓到，电视上和照片上看到背景有好多人，不表明这些人是去抓贪官的，那地方就该有很多人。如果是在衙门里，有一大帮人堵在那里，那是个好现象，证明人们对这个贪官义愤填膺，有觉悟。这个地方以后对贪官的治理会容易很多。所以俺觉得，在淋巴结里看到T细胞应该的。看的得报告里都有。
FL的预后可以根据FLIPI（FL international prognostic index)作出判断。有兴趣的可去查查
?3.ASCO现代肿瘤学5
2014-10-30 肿瘤医学论坛
作为美国临床肿瘤学会（ASCO）50周年庆典活动的一部分，ASCO列出了在重要里程碑时间轴上、最重大的
临床肿瘤进展，之后邀请医生、患者以及公众投票选出他们认为的过去50年里最有意义的5项现代肿瘤学进
展。目前ASCO公布了投票结果。ASCO主席Peter Yu在声明中谈道：“所有这些进步都标志着癌症医疗的重大
进步，并拯救了无数人的生命。”（源自Medscape网站）
以下是票选出来的“现代肿瘤学的5大进展”：
1、化疗治愈晚期霍奇金淋巴瘤
四药联合化疗方案——MOPP（环磷酰胺、长春新碱、氮芥和强的松）对于半数以上侵袭性霍奇金淋巴瘤
患者都能诱导长期缓解，这项研究于1965年带来了在成人晚期癌症化疗领域的首次突破。该方案很快成为了霍奇金淋巴瘤的标准治疗，但在20世纪七十年代，另一种不同的四药联合——ABVD（阿霉素、博莱霉素、长春花碱和氮烯咪胺）被证实更有效，能治愈70%的该类患者，成为当今治疗的主要方案。ASCO指出，于1965年发现的MOPP方案带来了第一次希望——晚期癌症可以通过药物治疗治愈，为当今这类患者90%的治愈率铺平了道路。
2、HPV疫苗被批准用来预防宫颈癌
2006年，美国食品药品监督管理局（FDA）批准了第一个HPV疫苗：Gardasil。这个疫苗可以针对造成
70%宫颈癌的两种HPV（16和18）以及另外两种与生殖器疣相关的HPV（6和11）产生免疫。Gardasil被批准
用于预防HPV相关的宫颈癌后，还被扩大用于预防其它的HPV相关疾病，包括女性阴道、会阴、肛门癌和男性
肛门癌、生殖器疣。ASCO补充指出：目前有研究认为，HPV感染与头颈部癌有关联，这提示HPV疫苗可能
也有助于预防这类癌症。如果能全面实施疫苗接种，将会显著减少世界各地宫颈癌和HPV相关癌症的发生率。
3、靶向药物转变了慢性髓系白血病的治疗
2001年，美国FDA对伊马替尼的快速审议和批准，使慢性髓系白血病（CML）的治疗发生了根本性的改
变。这种口服药物靶向作用于几乎所有伴有的基因缺陷（Ph小体）的CML患者，将一个几乎没有患者能长期存
活的绝症转变为5年生存率达90%的疾病。伊马替尼也开辟了对多种肿瘤进行分子靶向治疗的新时代。
4、化疗治愈睾丸癌
一项新的三药联合化疗方案——PVB（顺铂、长春新碱和博来霉素）能够使70%的进展期睾丸癌患者获得
完全缓解，部分得到治愈。而早期的化疗方案仅对5%男性患者有用。这种联合方案加上之后的手术、放疗和
化疗的进展，使睾丸癌成为最容易治愈的肿瘤之一以及肿瘤学上最成功的案例之一。
5、强效止吐药物明显改善患者的生活质量
1991年获得FDA批准的止吐药昂丹司琼以及随后几年陆续获得批准的其它支持治疗药物，使肿瘤治疗的经
过发生了根本改变，患者的生活质量得到了空前改善。昂丹司琼为5-羟色胺3受体拮抗剂，可阻断神经系统触
发的呕吐反射，其类似药物包括格拉司琼、多拉司琼、帕洛诺司琼。它们和其它止吐药如阿瑞匹坦一起，使大
多数癌症患者可接受门诊化疗。这些药物不仅缓解了化疗导致的严重呕吐，而且可能使患者避免常规的住院，
帮助他们完成全部治疗疗程，从而活得更长、更美好。
4.人类与癌症斗争的250年
http://bbs.wenxuecity.com/health/537604.html
250 Years of Advances Against Cancer (Text-Only Version)
During the past 250 years, we have witnessed many remarkable advances against cancer, a disease known to humanity for thousands of years. Here are a few key milestones in the history of cancer research.
1775: Chimney Soot & Squamous Cell Carcinoma
Percivall Pott identifies a relationship between exposure to chimney soot and the incidence of squamous cell carcinoma of the scrotum among chimney sweeps. His report is the first to clearly link an environmental exposure to the development of cancer.
1863: Inflammation & Cancer
Rudolph Virchow identifies white blood cells (leukocytes) in cancerous tissue, making the first connection between inflammation and cancer. Virchow also coins the term "leukemia" and is the first person to describe the excess number of white blood cells in the blood of patients with this disease.
1882: The First Radical Mastectomy to Treat Breast Cancer
William Halsted performs the first radical mastectomy to treat breast cancer. This surgical procedure remains the standard operation for breast cancer until the latter half of the 20th century.
1895: The First X-Ray
Wilhelm Roentgen discovers X-rays. The first X-ray picture is an image of one of his wife's hands.
1898: Radium & Polonium
Marie and Pierre Curie discover the radioactive elements radium and polonium. Within a few years, the use of radium in cancer treatment begins.
1902: Cancer Tumors & Single Cells with Chromosome Damage
Theodor Boveri proposes that cancerous tumors arise from single cells that have experienced chromosome damage and suggests that chromosome alterations cause the cells to divide uncontrollably.
1903: The First Use of Radiation Therapy to Cure Cancer
S.W. Goldberg and Efim London describe the use of radium to treat two patients with basal cell carcinoma of the skin. The disease was eradicated in both patients.
1909: Immune Surveillance
"Paul Ehrlich proposes that the immune system usually suppresses tumor formation, a concept that becomes known as the ""immune surveillance"" hypothesis. This proposal prompts research, which continues today, to harness the power of the immune system to fight cancer.
1911: Cancer in Chickens
Peyton Rous discovers a virus that causes cancer in chickens (Rous sarcoma virus), establishing that some cancers are caused by infectious agents.
1915: Cancer in Rabbits
Katsusaburo Yamagiwa and Koichi Ichakawa induce cancer in rabbits by applying coal tar to their skin, providing experimental proof that chemicals can cause cancer.
1928: The Pap Smear
George Papanicolaou discovers that cervical cancer can be detected by examining cells from the vagina under a microscope. This breakthrough leads to the development of the Pap test, which allows abnormal cervical cells to be detected and removed before they become cancerous.
1932: The Modified Radical Mastectomy for Breast Cancer
David H. Patey develops the modified radical mastectomy for breast cancer. This surgical procedure is less disfiguring than the radical mastectomy and eventually replaces it as the standard surgical treatment for breast cancer.
1937: The National Cancer Institute (NCI)
Legislation signed by President Franklin D. Roosevelt establishes the National Cancer Institute (NCI).
1937: Breast-Sparing Surgery Followed by Radiation
George Keynes describes the treatment of breast cancer with breast-sparing surgery followed by radiation therapy. After surgery to remove the tumor, long needles containing radium are inserted throughout the affected breast and near the adjacent axillary lymph nodes.
1941: Hormonal Therapy
Charles Huggins discovers that removing the testicles to lower testosterone production or administering estrogens causes prostate tumors to regress. Such hormonal manipulation—more commonly known as hormonal therapy—continues to be a mainstay of prostate cancer treatment.
1947: Antimetabolites
Sidney Farber shows that treatment with the antimetabolite drug aminopterin, a derivative of folic acid, induces temporary remissions in children with acute leukemia. Antimetabolite drugs are structurally similar to chemicals needed for important cellular processes, such as DNA synthesis, and cause cell death by blocking those processes.
1949: Nitrogen Mustard
The Food and Drug Administration (FDA) approves nitrogen mustard (mechlorethamine) for the treatment of cancer. Nitrogen mustard belongs to a class of drugs called alkylating agents, which kill cells by chemically modifying their DNA.
1950: Cigarette Smoking & Lung Cancer
Ernst Wynder, Evarts Graham, and Richard Doll identify cigarette smoking as an important factor in the development of lung cancer.
1953: The First Complete Cure of a Human Solid Tumor
Roy Hertz and Min Chiu Li achieve the first complete cure of a human solid tumor by chemotherapy when they use the drug methotrexate to treat a patient with choriocarcinoma, a rare cancer of the reproductive tissue that mainly affects women.
1958: Combination Chemotherapy
NCI researchers Emil Frei, Emil Freireich, and James Holland and their colleagues demonstrate that combination chemotherapy with the drugs 6-mercaptopurine and methotrexate can induce partial and complete remissions and prolong survival in children and adults with acute leukemia.
1960: The Philadelphia Chromosome
Peter Nowell and David Hungerford describe an unusually small chromosome in the cancer cells of patients with chronic myelogenous leukemia (CML). This chromosome, which becomes known as the Philadelphia chromosome, is found in the leukemia cells of 95% of patients with CML.
1964: A Focus on Cigarette Smoking
The U.S. Surgeon General issues a report stating that cigarette smoking is an important health hazard in the United States and that action is required to reduce its harmful effects.
1964: The Epstein-Barr virus
For the first time, a virus—the Epstein-Barr virus (EBV)—is linked to a human cancer (Burkitt lymphoma). EBV is later shown to cause several other cancers, including nasopharyngeal carcinoma, Hodgkin lymphoma, and some gastric (stomach) cancers.
1971: The National Cancer Act
On December 23, President Richard M. Nixon signs the National Cancer Act, which authorizes the NCI Director to coordinate all activities of the National Cancer Program, establish national cancer research centers, and establish national cancer control programs.
1976: The DNA of Normal Chicken Cells
Dominique Stehelin, Harold Varmus, J. Michael Bishop, and Peter Vogt discover that the DNA of normal chicken cells contains a gene related to the oncogene (cancer-causing gene) of avian sarcoma virus, which causes cancer in chickens. This finding eventually leads to the discovery of human oncogenes.
1978: Tamoxifen
The Food and Drug Administration (FDA) approves tamoxifen, an antiestrogen drug originally developed as a birth control treatment, for the treatment of breast cancer. Tamoxifen represents the first of a class of drugs known as selective estrogen receptor modulators, or SERMs, to be approved for cancer therapy.
1979: The TP53 Gene
The TP53 gene (also called p53), the most commonly mutated gene in human cancer, is discovered. It is a tumor suppressor gene, meaning its protein product (p53 protein) helps control cell proliferation and suppress tumor growth.
1984: HPV 16 & 18
DNA from human papillomavirus (HPV) types 16 and 18 is identified in a large percentage of cervical cancers, establishing a link between infection with these HPV types and cervical carcinogenesis.
1985: Breast-Conserving Surgery
Results from an NCI-supported clinical trial show that women with early-stage breast cancer who were treated with breast-conserving surgery (lumpectomy) followed by whole-breast radiation therapy had similar rates of overall survival and disease-free survival as women who were treated with mastectomy alone.
1986: HER2 Oncogene Cloning
The human oncogene HER2 (also called neu and erbB2) is cloned. Overexpression of the protein product of this gene, which occurs in about 20% to 25% of breast cancers (known as HER2-positive breast cancers), is associated with more aggressive disease and a poor prognosis.
1993: Guaiac Fecal Occult Blood Testing (FOBT)
Results from an NCI-supported clinical trial show that annual screening with guaiac fecal occult blood testing (FOBT) can reduce colorectal cancer mortality by about 33%.
1994: BRCA1 Tumor Suppressor Gene Cloning
The tumor suppressor gene BRCA1 is cloned. Specific inherited mutations in this gene greatly increase the risks of breast and ovarian cancer in women and the risks of several other cancers in both men and women.
1995: BRCA2 Tumor Suppressor Gene Cloning
The tumor suppressor gene BRCA2 is cloned. Similar to BRCA1, inheriting specific BRCA2 gene mutations greatly increases the risks of breast and ovarian cancer in women and the risks of several other cancers in both men and women.
1996: Anastrozole
The Food and Drug Administration (FDA) approves anastrozole for the treatment of estrogen receptor-positive advanced breast cancer in postmenopausal women. Anastrozole is the first aromatase inhibitor (a drug that blocks the production of estrogen in the body) to be approved for cancer therapy.
1997: Rituximab
The Food and Drug Administration (FDA) approves rituximab, a monoclonal antibody, for use in patients with treatment-resistant, low-grade or follicular B-cell non-Hodgkin lymphoma (NHL). Rituximab is later approved as an initial treatment for these types of NHL, for another type of NHL called diffuse large B-cell lymphoma, and for chronic lymphocytic leukemia.
1998: NCI-Sponsored Breast Cancer Prevention Trial
Results of the NCI-sponsored Breast Cancer Prevention Trial show that the antiestrogen drug tamoxifen can reduce the incidence of breast cancer among women who are at increased risk of the disease by about 50%. The Food and Drug Administration (FDA) approves tamoxifen to reduce the incidence of breast cancer in women at increased risk.
1998: Trastuzumab
The Food and Drug Administration (FDA) approves trastuzumab, a monoclonal antibody that targets cancer cells that overproduce the protein HER2, for the treatment of women with HER2-positive metastatic breast cancer. Trastuzumab is later approved for the adjuvant (post-operative) treatment of women with HER2-positive early-stage breast cancer.
2001: Imatinib Mesylate
Results of a clinical trial show that the drug imatinib mesylate, which targets a unique protein produced by the Philadelphia chromosome, is effective against chronic myelogenous leukemia (CML). Later, it is also shown to be effective in the treatment of gastrointestinal stromal tumors (GIST).
2003: NCI-Sponsored Prostate Cancer Prevention Trial (PCPT)
Results of the NCI-sponsored Prostate Cancer Prevention Trial (PCPT) show that the drug finasteride, which reduces the production of male hormones in the body, lowers a man's risk of prostate cancer by about 25%.
2006: NCI's Study of Tamoxifen and Raloxifene (STAR)
Results of NCI's Study of Tamoxifen and Raloxifene (STAR) show that postmenopausal women at increased risk of breast cancer can reduce their risk of developing the disease if they take the antiestrogen drug raloxifene. The risk of serious side effects is lower with raloxifene than with tamoxifen.
2006: Gardasil
The Food and Drug Administration (FDA) approves the human papilloma virus (HPV) vaccine Gardasil, which protects against infection by the two types of HPV that cause approximately 70% of all cases of cervical cancer. NCI scientists developed the underlying technology used to make Gardasil.
2009: Cervarix
The Food and Drug Administration (FDA) approves Cervarix, a second vaccine that protects against infection by the two types of the human papilloma virus (HPV) that cause approximately 70% of all cases of cervical cancer worldwide. NCI scientists developed the underlying technology used to make Cervarix.
2010: The First Human Cancer Treatment Vaccine
The Food and Drug Administration (FDA) approves sipuleucel-T, a cancer treatment vaccine that is made using a patient's own immune system cells (dendritic cells), for the treatment of metastatic prostate cancer that no longer responds to hormonal therapy. It is the first (and so far only) human cancer treatment vaccine to be approved.
2010: NCI-Sponsored Lung Cancer Screening Tiral (NLST)
Initial results of the NCI-sponsored Lung Cancer Screening Trial (NLST) show that screening with low-dose helical computerized tomography (CT) reduced lung cancer deaths by about 20% in a large group of current and former heavy smokers.
2011: Ipilimumab
The Food and Drug Administration (FDA) approves the use of ipilimumab, a monoclonal antibody, for the treatment of inoperable or metastatic melanoma. Ipilimumab stimulates the immune system to attack cancer cells by removing a "brake" that normally controls the intensity of immune responses.
2012: NCI-Sponsored PLCO Cancer Screening Trial
Results of the NCI-sponsored PLCO Cancer Screening Trial confirm that screening people 55 years of age and older for colorectal cancer using flexible sigmoidoscopy reduces colorectal cancer incidence and mortality. In the PLCO, screened individuals had a 21% lower risk of developing colorectal cancer and a 26% lower risk of dying from the disease than the control subjects.
2013: Ado-Trastuzumab Emtansine (T-DM1)
The FDA approves ado-trastuzumab emtansine (T-DM1) for the treatment of patients with HER2-positive breast cancer who were previously treated with trastuzumab and/or a taxane drug. T-DM1 is an immunotoxin (an antibody-drug conjugate) that is made by chemically linking the monoclonal antibody trastuzumab to the cytotoxic agent mertansine, which inhibits cell proliferation by blocking the formation of microtubules.
2014: Analyzing DNA in Cancer
Researchers from The Cancer Genome Atlas (TCGA) project, a joint effort by NCI and the National Human Genome Research Institute to analyze the DNA and other molecular changes in more than 30 types of human cancer, find that gastric (stomach) cancer is actually four different diseases, not just one, based on differing tumor characteristics. This finding from TCGA and other related projects may potentially lead to a new classification system for cancer, in which cancers are classified by their molecular abnormalities as well as their organ or tissue site of origin.
2014: Pembrolizumab
The FDA approves pembrolizumab for the treatment of advanced melanoma. This monoclonal antibody blocks the activity of a protein called PD1 on immune cells, which increases the strength of immune responses against cancer.
美国食品和药物管理局（FDA）批准sipuleucel-T，即利用患者自身的免疫系统的细胞（树突状细胞）制成，转移性前列腺癌的治疗中不再响应激素治疗的癌症治疗疫苗。这是第一个（也是迄今为止唯一）人体癌症治疗疫苗获得批准。
2010：NCI赞助的肺癌筛查Tiral（NLST）
美国国立癌症研究所赞助的肺癌筛查试验（NLST）的初步结果表明，低剂量螺旋计算机断层扫描（CT）筛选一大群现任和前任重度吸烟者降低肺癌的死亡率约20％。
2011：易普利姆玛
美国食品和药物管理局（FDA）批准的使用易普利姆玛的，单克隆抗体，为不可??操作的或转移性黑色素瘤的治疗。易普利姆玛刺激免疫系统通过去除一个“刹车”，通常控制免疫反应的强度，攻击癌细胞。
2012：NCI赞助PLCO癌症筛查试验
美国国立癌症研究所赞助的PLCO癌症筛查试验结果证实，采用乙状结肠镜筛查的人55岁及以上的大肠癌降低大肠癌的发病率和死亡率。在PLCO，甄别个人有发展大肠癌这种疾病比对照受试者死亡的降低26％的风险的降低21％的风险。
2013：ADO-曲妥珠单抗Emtansine（T-DM1）
美国FDA对患者的治疗HER2阳性乳腺癌谁以前与曲妥珠单抗和/或紫杉烷类药物治疗的批准ADO-曲妥珠单抗emtansine（T-DM1）。的T-DM1是免疫毒素（一种抗体 - 药物偶联）由化学连接的单克隆抗体曲妥单抗对细胞毒性剂mertansine，其通过阻断微管的形成抑制细胞增殖制成。
2014年：癌症的DNA分析
从癌症基因组图谱（TCGA）项目，形成工作合力由NCI和国家人类基因组研究所分析DNA，并在全球30多个类型的人类癌症等的分子变化，发现胃（胃）的癌症研究人员实际上是4不同的疾病，不只是一个，根据不同肿瘤的特点。这一发现从TCGA等相关项目可能潜在地导致一个新的分类系统的癌症，其中癌症是按它们的分子异常以及原籍器官或组织部位。
2014年：Pembrolizumab
美国食品药物管理局批准pembrolizumab用于晚期黑色素瘤的治疗。此单克隆抗体块称为PD1上的免疫细胞的蛋白质，这增加了对癌症的免疫应答的强度的活性。
==
靶向治疗的药物可能会越来越多，随着我们对肿瘤的认识进一步的加深，开发了越来越多的药物，可能在今后的几年当中会逐步增加，我们可以分为几大类， 第一类是针对血管的，长到成人以后血管不会再长了，成人以后血管也成熟了，肿瘤需要不断的新生血管来提供，所以新生血管是肿瘤的特征，在靶向药物当中大概 有28％是针对这个系统的，所以我们讲进入临床比较快的有几个药物，比如一个是贝伐单抗以外我们还有CT6474，第二是作用于信号传导通路的，肿瘤为什 么生长要由信号传递，如果信号打断了肿瘤就会死亡了，比较常见的是表皮生长因子，比如叫易瑞沙，特罗凯都能在国内市场上买到，还有其他的药物可能在不久的 将来会进入临床。
|
|
|
|
|
Glomus tumor is a benign mesenchymal neoplasm comprising less than 2% of soft tissue tumors. It is composed of cells resembling modified smooth muscle cells of the normal glomus body. The glomus body, a thermoregulator, is a specialized form of arteriovenous anastomosis localized in dermal and precoccygeal soft tissue. Although glomus tumors are rare neoplasms, clinical misdiagnosis of many of these lesions as hemangiomas or venous malformations makes an accurate assessment of their actual prevalence difficult. A malignant counterpart of this lesion exists but is extremely rare.
血管球瘤是一种良性间质肿瘤，包括软组织肿瘤小于2％。它是由细胞类似于正常血管球体的改性平滑肌细胞。存在这种病变的恶性对口，但极为罕见。
==疮痈肠痈浸淫病脉证并治第十八http://www.haodf.com/zhuanjiaguandian/zhaodongqi_854358018.htm
金匮要略浅注 清·陈修园
（两手）诸（部．俱见）浮数（之）脉．（浮主表．数主热．若表邪）应当发热．（今不发热．） 而反洒淅恶寒．（必其气血凝滞．即经所谓营气不从．逆于肉理．乃生痈肿．阳气有余．营气不行．乃发为痈是也．）若有痛处．（更明明可验．然而痈者．壅也． 欲通其壅．）当（以麻黄荆芥之类．透）发其（凝滞之）痈．师曰．诸痈肿．欲知有脓无脓．以手掩肿上．热者（毒已聚．）为有脓．不热者．（毒不聚．）为无 脓．
此言痈之所由成．而并辨有脓无脓也．言外见痈之已成者．欲其溃．未成者． 之起也．
内外原不分科．分之者．以针砭刀割熏洗等法．另有传习谙练之人．士君子置而弗道．然而大证．断非外科之专门者．所能治也．薛氏医按．论之最详．然以 六味丸八味丸补中益气汤十全大补汤归脾汤六君子汤异功汤逍遥散等剂．出入加减．若溃后虚证颇宜．其实是笼统套法．于大证难以成功．金匮谓浮数脉．当发热而反恶寒者．以卫气有所遏而不出．卫有所遏．责在荣之过实．止此数语寥廖．已寓痈肿之绝大治法．再参六经之见证．六经之部位．用六经之的方．无有不效．外科之专门．不足恃也．
肠痈之为病．（气血为内痈所夺．不得外荣肌肤．故）其身（枯皱．如鳞）甲（之交）错．腹皮（虽）急．（而）按之（则）濡．（其外虽）如肿状．（而 其）腹（则）无积聚．（其）身（虽）无热．（而其）脉（则似表邪之）数．此为（营郁成热．）肠内有痈脓．（以）薏苡附子败酱散主之．（此痈之在于小肠 也．）
此为小肠痈而出其方治也．败酱一名苦菜．多生土墙及屋瓦上．闽人误为蒲公英．
薏苡附子败酱散方
薏苡仁（十分） 附子（二分） 败酱（五分）。上三味．杵为散．取方寸匕．以水二升．煎减半．顿服．小盒饭下．
（痈之在于大肠者．何如．大肠居于小肠之下．若）肿（高而）痈（甚）者．（逼处膀胱．致）少腹肿痞．按之即痛如淋．（而实非膀胱为害．故）小便（仍见）自调．（小肠为心之合．而气通于血脉．大肠为肺之合．而气通于皮毛．故彼脉数身无热．而此则）时时发热自汗出．复恶寒．（再因其证而辨其脉．若）其脉迟紧者．（邪暴遏而营未变．为）脓未成．可下之．（令其消散．若其）脉洪数者（毒已聚而营气腐．为）脓已成．（虽下之．亦不能消．故）不可下也．（若）大黄牡丹汤（不论痈之已成未成．皆可）主之．
此为大肠痈而出其方治也．
大黄牡丹汤方
大黄（四两） 牡丹（一两） 桃仁（五十个） 冬瓜仁（半升） 芒硝（三合）
上五味．以水六升．煮取一升．去滓．内芒硝．再煎沸．顿服之．有脓当下．如无脓．当下血．
问曰．寸口脉浮微而涩．法当亡血．若汗出．设不汗出者．云何．曰、（血与汗．皆阴也．微为阳弱．涩为血少．）若身有疮．被刀斧所伤．（而）亡血（血亡而气亦无辅．此脉微而又涩之）故也．（且夺血者无汗．此脉浮而不汗出之故也．）
此为金疮亡血辨其脉也．
（凡一切）病金疮．（统以）王不留行散主之．
此为金疮出其总治之方也．
徐忠可云、此非上文伤久无汗之金疮方．乃概治金疮方也．故曰、病金疮．王不留行散主之．盖王不留行．性苦平．能通利血脉．故反能止金疮血．逐痛．蒴 亦通利气血．尤善开痹．周身肌肉肺主之．桑根白皮最利肺气．东南根向阳．生气尤全．以复肌肉之生气．故以此三物甚多为君．甘草解毒和荣．尤多为臣．椒姜以 养其胸中之阳．浓朴以疏其内结之气．芩芍以清其阴分之热为佐．若有风寒．此属经络客邪．桑皮止利肺气．不能逐外邪．故勿取．（孙男心兰按．金疮亡血者忌发 汗．以阴伤故也．若偶感风邪．其人不省．仍宜以破伤风论治．勿泥于亡血之禁．）
王不留行散方
王不留行（十分八月八日采） 蒴 细叶（十分七月七日采） 桑东南根（白皮十分三月三日采） 甘草（十八分） 黄芩（二分） 川椒（三分） 浓朴（二分） 干姜（二分） 芍药（二分）
上九味．王不留行蒴 桑皮三味．烧灰存性．各别杵筛．合治之为散．服方寸匕．小疮即粉之．大疮但服之．产后亦可服．
排脓散方
枳实（十六枚） 芍药（六分） 桔梗（二分）
上三味．杵为散．取鸡子黄一枚．以药散与鸡黄相等．揉和令相得．饮和服之．日一服．
枳实得阳明金气以制风．禀少阴水气以清热．又合芍药以通血．合桔梗以利气．而尤赖鸡子黄之养心和脾．取有情之物．助火土之脏阴．以为排脓化毒之本也．
排脓汤方
甘草（二两） 桔梗（三两） 生姜（一两） 大枣（十枚）。上四味．以水三升．煮取一升．温服五合．日再服．
此亦行气血和营卫之剂．
浸淫疮．（留流不已．俗名棉花疮杨梅疮恶疠之类．）从口起．流向四肢者．可治．（以其从内走外也．）从四肢流来入口者．不可治．（以其从外走内也．）浸淫疮．（以）黄连粉主之．（方未见）
此为浸淫疮出其方治也．方未见．疑即黄连一味为粉．外敷之．甚者亦内服之．诸疮痛痒．皆属心火．黄连苦寒泻心火．所以主之．余因悟一方．治杨梅疮棉 花等疮甚效．连翘蒺藜黄 金银花各三钱．当归甘草苦参荆芥防风各二钱．另用土茯苓二两．以水煮汤去滓．将此汤煮药．空心服之．十日可愈．若系房欲传染者．其毒乘肾气之虚．从精孔深 入中肾．散于冲任督脉．难愈．宜加龟板入任．生鹿角末入督．黄柏入冲等药．并先用黑牵牛制末．作小丸．和烧 散．以土茯苓汤送下．令黑粪大下后．再加前汤如神．
==王连癌症偏方：
材料：五灵脂100克、香附子100克、黑牵牛200克、木香100克。
用法：把以上几种药物，全部加工成粉末，然后，将粉末用白醋调匀，制成药丸，一个药丸，按10克的分量制作。患者，每天吃一个药丸。吃的时候，用姜汁送服，姜汁，就是用姜片煮出的浓姜汤。每天吃三到四次，连用一个月，就能有效果，坚持服用，就会治愈。使用此方时忌服人参。孕妇和产妇不能用此方。这个方子，曾治好过两个人的癌症。一个是直肠癌患者，一个是肺癌患者。
==仙鹤草
明代蒋仪将仙鹤草用于治疗食道癌和胃癌,“滚咽隔之痰，平翻胃之秽”，咽隔翻胃是古人用以形容食道癌和胃癌的病症，“从来医者群相畏惧，以为不治之症。”“余得此剂，十投九效”癌症患者服食仙鹤草后，如“饥荒之粟，隆冬之裘”。
现代医学研究发现，仙鹤草提取液对小鼠肉瘤S—180，黑色素瘤B—22，B—16，瓦克氏瘤W—256，海蓝癌细胞等均有较强的抑制作用，对小鼠腹水癌亦有治疗效果。据分析，仙鹤草提取液至少含有12种成分，其大部分均呈抗癌性。《朝日新闻》曾报导：日本在筛选近千种天然药物中，得到3种抗癌性最高的活性物质，其中之一就是仙鹤草。《汉方研究》认为：传统的化疗药既杀伤癌细胞也杀伤癌细胞，而仙鹤草既可杀伤癌细胞，又有利于正常细胞，实属一种罕见的抗癌中药。
採用仙鹤草治疗癌症时，应使用地上全草去根，每次120克，大枣100枚，粳米(或糯米)100克，入砂锅中煎取浓汁500毫升，待粳米与大枣煮粥快成时，兑入仙鹤草汁，者沸后食用，每日2次，连服1—2个月。
==九十三岁的彝医大师曲苓章的祖传秘方治疗乳房肿块、子宫肌瘤、卵巢囊肿：
取三七75克，香附75克，鼠妇虫30克、碎成细未混匀备用。选五香血藤600克、鸡矢藤600克、金荞麦600克、加水煎熬三次合并熬成稠膏，最后加入上述细粉，混合均匀即可服用。（市面上也有叫做泰康消结片是同一方药组成）。
==所载药方在肺癌治疗中均收到满意疗效
1、石仙桃30克
2、（治疗晚期肺癌）生黄芪21克
3、华蟾10克
4、（晚期肺癌）生黄芪40克
==我的一位亲戚今年就八十岁了，二十多年以前患胃癌，在栖霞市人民医院做了胃癌切除及周围淋巴结大清扫手术。出院回家后三个多月，病情加重，经查胃癌复发转移到肝、肺等。医生说无法治了。用此方烧水当茶喝，二十多年来，一直活得挺好。特别是在医院做了手术以后，被医生判为“死刑”的病人，服用这个方子，有的几年十几年后仍然健在，有的虽然死了，也延长寿命二、三年不等。 灵芝10—20克、槐树枝用剪子剪一寸长5—10节，煎泡水当茶饮，每1—2日一付，或者泡至药水无色味再换。
==用半枝莲200克，白花蛇舌草300克，分为8等份，每份煮沸2暖瓶水，煮沸二小时，热饮，不能喝水、喝茶。
附录：常见食物的酸碱性 1.强酸性食品：蛋黄、奶酪、白糖做的西点或柿子、乌鱼子、柴鱼等。 2.中酸性食品：火腿、培根、鸡肉、鲔鱼、猪肉、鳗鱼、牛肉、面包、小麦、奶油、马肉等。 3.弱酸性食品：白米、落花生、啤酒、酒、油炸豆腐、海苔、文蛤、章鱼,泥鳅。
4.弱碱性食品：红豆、萝卜、苹果、甘蓝菜、 洋葱、豆腐等。 5.中碱性食品：萝卜干、大豆、红萝卜、蕃茄、 香蕉、橘子、番瓜、草莓、蛋白、梅干、柠檬、菠菜等。 6.强碱性食品：葡萄、茶叶、葡萄酒、海带芽、海带等。 尤其是天然绿藻富含叶绿素，是不错的碱性健康食品，而茶类不宜过量，最佳饮用时间为早上。
化疗食品：http://linbaai.tumorhome.com/hualiao/2894.html
